Quick Index
COVID-19 Vaccination and Treatment Guidance
Policies and standards related to the COVID-19 vaccines that Infection Prevention and Control professionals may use to support their own documentation and best practices during the COVID-19 Pandemic.
COVID-19 Vaccination Tracker
As of May 16, 2022 more than 11.5 billion vaccines doses have been administered globally. In Canada, 84,559,822 doses of approved COVID-19 vaccines have been administered. In total, 84.86% of the Canadian population has received at least one dose, 81.64% have received at least two doses and 48.33% of the Canadian population has been fully vaccinated with the third dose of vaccine. Source: COVID-19 Vaccination in Canada (PHAC)
For more information refer to:
- COVID-19 Vaccination in Canada
- COVID-19 Vaccinations (Our World in Data)
- Tracking Coronavirus Vaccination Around the World (New York Times)
COVID-19 Vaccine Guidance
- Quick reference guide on use of COVID-19 vaccines
- Statement from the Council of Chief Medical Officers of Health (CCMOH): Interchangeability of Authorized COVID-19 Vaccines
- International Coalition of Medicines Regulatory Authorities statement on continuation of vaccine trials
- Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines
- Guidance on booster COVID-19 vaccine doses in Canada – Update December 3, 202
- Statement from the Council of Chief Medical Officers of Health (CCMOH): Update on the Use of COVID-19 Vaccine Boosters and on COVID-19 Vaccines and the Risk of Myocarditis and Pericarditis
- Health Canada authorizes Medicago COVID-19 vaccine for adults 18 to 64 years of age
- Details for: COVIFENZ - COVID-19
- Vaccine uptake in Canadian adults 2021
- Statement from the Council of Chief Medical Officers of Health (CCMOH) on the importance of staying up to date with COVID-19 vaccines
- COVID-19 vaccination highly effective in individuals with immune-related inflammatory diseases
- COVID-19 Immunity Task Force: SeroTracker
National Advisory Committee on Immunization (NACI) COVID-19 Guidance
- NACI Preliminary guidance on key populations for early COVID-19 immunization
- NACI rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series
- NACI rapid response: Booster dose in long-term care residents and seniors living in other congregate settings
- NACI: Recommendations on the use of COVID-19 Vaccines
- NACI Statement: Interim guidance on booster COVID-19 vaccine doses in Canada
- NACI Statment: Recommendations on the use of COVID-19 vaccines
- NACI: Rapid Response Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccine
- NACI: Guidance on booster COVID-19 vaccine doses in Canada
- NACI: Summary of the updated vaccine statement -MRNA COVID-19 Vaccines and Myocarditis
- NACI Statement: Interim guidance on booster COVID-19 vaccine doses in Canada
- NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
- NACI: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age
- NACI: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply
- NACI: Summary of Extended Dose Intervals Statement of April 7, 2021
- NACI rapid response: Recommended use of AstraZeneca COVID-19 vaccine in younger adults
- Summary of the NACI Statement -Recommendation on the use of the PfizerBioNTech COVID-19 Vaccine in children 5-11 years of age
- NACI Rcommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age
- NACI: Rapid Response: Guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age
- NACI: Summary of the NACI rapid response of January 28, 2022
- NACI Statement: Recommendations on the use of Medicago COVID-19 vaccine (Covifenz
- Summary of the NACI statement of March 11, 2022
- NACI Statement: Initial guidance on a second booster dose of COVID-19 vaccines in Canada
- NACI Statement: Updated guidance on a first booster dose of COVID-19 vaccines in Canada
- NACI Summary: Updated guidance on a first booster dose of COVID-19 vaccines in Canada
Vaccine Development and Rollout
- COVID-19: How vaccines are developed
- Vaccine development and approval in Canada
- Vaccines and treatments for COVID-19: Vaccine rollout
- VaccineConnect: IT system for managing vaccination rollout
Vaccine Storage Guidance and Administration Guidance
- Vaccines and treatments for COVID-19: Vaccine rollout
- For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines
- Health Canada authorizes more flexible storage conditions for Pfizer-BioNTech COVID-19 vaccine
- Vaccine safety, concerns and possible side effects
Information on COVID-19 Vaccines (Pfizer, Moderna, Astra Zeneca and Janssen)
-
Administration of Pfizer-BioNTech COVID-19 Vaccine (Ontario Health)
